Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Light Sciences Oncology has started treatment of patients with benign prostatic hyperplasia, or enlargement of the prostate, using Light Infusion Therapy, a light-activated drug treatment under development.
Subscribe to our email newsletter
Light Sciences Oncology (LSO) plans to conduct a 12-patient, Phase I/II dose-escalation study at four sites in the US as well as a 40-patient, Phase IIa study in Australia, expected to begin during the current quarter of 2008.
LSO is currently conducting Phase III clinical studies of Light Infusion Therapy (Litx) in patients with hepatoma and metastatic colorectal cancer and expects to initiate a Phase III clinical study in glioma in the second half of 2008.
Llew Keltner, president and CEO of LSO, said: “Treating patients with this serious quality-of-life problem is an important milestone for our Litx technology. We plan to continue to demonstrate the broader applicability of Litx beyond oncology.”